- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02162654
Remote Ischemic Preconditioning for Intracranial Aneurysm Treatment (RIPAT)
The Role of Remote Ischemic Preconditioning in the Prevention of Ischemic Brain Damage During Intracranial Aneurysm Treatment (RIPAT) - A Prospective Randomized Exploratory Study
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Prospective, randomized, double-blind, explorative single center clinical trial in patients subjected to the treatment of an un-ruptured intracranial aneurysm, either by surgical clipping or endovascular coiling. Goal of the study is to determine whether remote ischemic preconditioning (RIPC) prior to aneurysm treatment alters various biomarkers associated with ischemic central neuronal tissue damage. The trial takes place at Innsbruck University Hospital of Innsbruck Medical University, Innsbruck, Austria.
Patients fulfilling inclusion criteria are randomly allocated either to pre-interventional ischemic preconditioning (Group A = intervention group) or sham preconditioning (Group B = control group). RIPC is performed by inflating a blood pressure cuff around one upper extremity three times for five minutes with five minutes interval with the patient under general anesthesia prior to the start of the procedure.
Patients, all staff involved in diagnosis and treatment and all study members are blinded to the patients' group affiliation. The anesthesiologist and two staff members who perform preconditioning are not blinded.
Primary outcome is a difference of ± 2SD in the concentration-time curve of a panel of biochemical parameters indicative of cerebral ischemia (S100B, NSE, GFAP, MMP9, MBP, microparticles) in the first five days after the intervention. Secondary outcome parameters are changes in the post-interventional MRI and neuropsychological and clinical outcome at six and 12 months.
CONSORT and TIDieR guidelines will be followed. The trail will be registered in a public database. The trail protocol will be published in an open-access journal.
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Innsbruck, Østerrike, 6020
- Rekruttering
- Clinical Department of Neurosurgery, Innsbruck Medical University
-
Ta kontakt med:
- Martin Ortler, M.D., MSc.
- Telefonnummer: 80975 0043-512-504
- E-post: martin.ortler@i-med.ac.at
-
Ta kontakt med:
- Selma Tülü, Cand. med.
- E-post: selma.tuelue@student.i-med.ac.at
-
Hovedetterforsker:
- Martin Ortler, MD, MSc
-
Underetterforsker:
- Claudius Thomé, M.D.
-
Underetterforsker:
- Selma Tülü, Cand.med.
-
Underetterforsker:
- Miriam Mulino, M.D.
-
Underetterforsker:
- Daniel Pinggera, M.D.
-
Underetterforsker:
- Claudia Unterhofer, M.D.
-
Underetterforsker:
- Erich Schmutzhard, M.D.
-
Underetterforsker:
- Bettina Pfausler, M.D.
-
Underetterforsker:
- Ronny Beer, M.D.
-
Underetterforsker:
- Raimund Helbok, M.D.
-
Underetterforsker:
- Peter Lackner, M.D.
-
Underetterforsker:
- Thomas Benke, M.D.
-
Underetterforsker:
- Thomas Bodner, M.D.
-
Underetterforsker:
- Margarethe Delazer, M.D.
-
Underetterforsker:
- Raffaella Matteucci-Gothe, Ph.D.
-
Underetterforsker:
- Uwe Siewert, Ph.D.
-
Underetterforsker:
- Philipp Würtinger, M.D.
-
Underetterforsker:
- Andrea Griesmacher, M.D.
-
Underetterforsker:
- Markus Luger, M.D.
-
Underetterforsker:
- Arnulf Benzer, M.D.
-
Underetterforsker:
- Franz Wiedermann, M.D.
-
Underetterforsker:
- Astrid Grams, M.D.
-
Underetterforsker:
- Elke Gizewski, M.D.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Informed written consent of patient
- Age > 18 years
- Intracranial aneurysm, single or multiple, intervention as indicated by interdisciplinary vascular board (includes previously treated aneurysms)
- Normal baseline MRI
Exclusion Criteria:
- Clinical or radiological signs of subarachnoid hemorrhage
- Planned vessel sacrifice as the primary modality for aneurysm treatment
- Dissecting or mycotic aneurysm
- Previous history of stroke or TIA within the last six months
- Signs or symptoms of upper and lower extremity peripheral vascular illness
- Drugs and lifestyle factors that interfere with biomarker Determination
- Inability to complete neuropsychological testing for language reasons
- Patients unable to have an MRI scan for any reason
- Previous serious cerebral disease that would preclude completion of the protocol or preclude MRI analysis of small strokes
- Pregnancy
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Remote ischemic preconditioning
Inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
|
The blood pressure cuff is inflated to 200 mmHg for 3 x 5 minutes with 5 minutes of reperfusion by complete cuff deflation each.
|
|
Sham-komparator: Sham preconditioning
Sham inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
|
The blood pressure cuff is inflated to 10 mmHg for 3 x 5 minutes with 5 minutes of complete cuff deflation each.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Area-under-Curve for biomarkers in the first 5 days after aneurysm treatment(S100B, NSE, GFAP, NSE, MMP9, Microparticles)
Tidsramme: on admission, after preconditioning but prior to intervention, at completion of intervention, at hours 3, 6, 12, 24, 48, 72, 96, 120 after completion of intervention
|
Serum biomarkers reflect brain tissue ischemic damage with various specificity and sensitivity (see Whiteley 2008, Ahmad 2012) Advantages include (1) to be available early, (2) to be continuous variables (low study n), (3) they were able to demonstrate an effect of ischemic preconditioning in other clinical studies (see Koch 2010, Veighei 2012)
|
on admission, after preconditioning but prior to intervention, at completion of intervention, at hours 3, 6, 12, 24, 48, 72, 96, 120 after completion of intervention
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number (n) of new lesions in postinterventional MRI (DWI and FLAIR)
Tidsramme: preinterventional/on day 1 or 2
|
Outcome Parameter used in other clinical studies focussing on ischemia after neurointerventional procedures (e.g.
ENACT study)
|
preinterventional/on day 1 or 2
|
|
Clinical outcome ( National Institutes of Health Stroke Scale, NIHSS and modified Rankin Scale mRS)
Tidsramme: at discharge, at 6 and 12 months
|
Established outcome parameters for cerebrovascular studies.
Dichotomized into favourable (NIHSS ≤1, mRS 0-1) and unfavourable
|
at discharge, at 6 and 12 months
|
|
Volume (mm3) of new lesions in postinterventional MRI (DWI and FLAIR)
Tidsramme: preinterventional, postinterventional on day 1 or 2
|
As above for number of lesions
|
preinterventional, postinterventional on day 1 or 2
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Neuropsychological testing VLMTA (Verbaler Lern- und Merkfähigkeitstest), the WMS-R (Zahlenspanne vorwärts und rückwärts), trail making A and B tests, the Regensburger Wortflüssigkeitstest, the TAP Wechsel verbal, the TAP and the HADS-D)
Tidsramme: preinterventional, at 6 and 12 months
|
Standard tests used in patients with cerebrovascular disorders in our departments.
Not applicable to non-german-speaking patients.
|
preinterventional, at 6 and 12 months
|
|
Brain volume changes (MRI, voxel -based morphometry)
Tidsramme: Preinterventional/at the 12 months FU
|
Longterm brain volume changes that correlate with NP deficits (Horstmann 2010, Moskowitz 2011, Vuylsteke 2011) will be analyzed using voxel-based morphometry techniques
|
Preinterventional/at the 12 months FU
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Martin Ortler, M.D., MSc., Clinical Department of Neurosurgery, Innsbruck Medical University
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 20131101-823
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .